Prostate MR imaging: Tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters

Radiology

Volumn 252, Issue 1, 2009, Pages 101-108

  Franiel, Tobias ^a   Lüdemann, Lutz ^a   Rudolph, Birgit ^a   Rehbein, Hagen ^a   Stephan, Carsten ^a   Taupitz, Matthias ^a   Beyersdorff, Dirk ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; GADOLINIUM PENTETATE; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTERSTITIAL VOLUME; MALE; MEAN INTERSTITIAL AREA; MEAN VESSEL AREA; MEAN VESSEL DENSITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETERS OF MEASUREMENT AND ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE CHARACTERIZATION;

AGED; BLOOD FLOW VELOCITY; BLOOD VOLUME; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 67650091953     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2521081400     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007;25:3-9.
3. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
4. Beyersdorff D, Taymoorian K, Knosel T, et al. MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 2005;185:1214-1220.
5. Bostwick DG. Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
6. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993;24:220-226.
7. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-2551.
8. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-779.
9. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
10. Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK. Molecular markers and mortality in prostate cancer. BJU Int 2007;100:1259-1263.
11. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
12. Prochnow D, Beyersdorff D, Warmuth C, Taupitz M, Gemeinhardt O, Ludemann L. Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magn Reson Imaging 2005;23:983-990.
13. Rohlfing T, Russakoff DB, Denzler J, Mori K, Maurer CR. Progressive attenuation fields: fast 2D-3D image registration without precomputation. Med Phys 2005;32:2870-2880.
14. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
15. Franiel T, Ludemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol 2008;43:481-487.
16. Ludemann L, Grieger W, Wurm R, Wust P, Zimmer C. Quantitative measurement of leakage volume and permeability in gliomas, meningiomas and brain metastases with dynamic contrast-enhanced MRI. Magn Reson Imaging 2005;23:833-841.
17. Calamante F, Gadian DG, Connelly A. Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Magn Reson Med 2000;44:466-473.
18. Kershaw LE, Buckley DL. Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med 2006;56:986-992.
19. Haupt G, Haupt A, Richter KD, Senge T. New way to deliver fluids: endoscopic jet injection into the beagle prostate. J Urol 2003;170:2097-2100.
20. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53.
21. Schlemmer HP, Merkle J, Grobholz R, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309-317.
22. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814.
23. Kety SS. Theory of blood-tissue exchange and its application to measurement of blood flow. Meth Med Res 1960;8:223-227.
24. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14:457-463.
25. de Bazelaire C, Rofsky NM, Duhamel G, et al. Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol 2006;16:2083-2091.
26. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging - initial experience. Radiology 2004;233:709-715.
27. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain. II. Experimental validation. J Cereb Blood Flow Metab 1998;18:1378-1385.
28. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-465.
29. Rubin MA, Buyyounouski M, Bagiella E, et al. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999;53:542-547.
30. de la Taille A, Katz AE, Bagiella E, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy: a comparison of CD34 and CD31. Am J Clin Pathol 2000;113:555-562.
31. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 2004;20:279-287.
32. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109.
33. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.